10 research outputs found
Producing 'Human Elements Based Medical Technologies' in Biotech Companies: Some Ethical and Organisational Ingredients for Innovative Cooking
This article is based on the findings of an EU-funded qualitative research project, entitled 'From GMP to GBP: Fostering good bioethics practices [GBP] among the European biotechnology industry', which seeks to improve the understanding of bioethical issues through the observation of the daily practices in European biotechnology companies and proposes a methodology approaching ethical issues. The comparative study was carried out in biotech companies in France, Italy, Sweden, Hungary and Belgium which develop a wide range of new technologies, all of them involving human materials or where human subjects participate (in clinical trials). Based on our findings in these local settings, we suggest that the notion of bioethics and the way its production is theorised need to be re-conceptualised. We argue that material practices and moral statements are intermingled in inextricable ways that render the formation of bioethical concerns fully dependent on the organisational landscape in which it is embedded. More precisely, the here presented co-production model of moral statements and organisational practices presents a set of common factors that influence how bioethical discourses are shaped, despite the heterogeneity of their epistemic cultures. For example, the procedural design of cell-based-products, the modes of collecting and storing biological specimen, the relationship between patients and companies and technological transfers to emerging countries are defining components that contribute to the shaping process of bioethical concerns. Thus, the path dependency of bioethical concerns relies on an already existing, specific infrastructure and existing relationships within and outside a company rather than on external judgement subsequently applied to its objects, or a collection of processes of reasoning coming from external institutions
Framing and legitimating EU legal regulation of human gene-editing technologies: key facets and functions of an imaginary
Copyright © The Author(s) 2021. Gene-editing technologies, ie those able to make changes in the DNA of an organism, are the object of global competition and a regulatory race between countries and regions. There is an attempt to craft legal frameworks protective enough for users, but flexible enough for developers of gene-editing technologies. This article examines the imaginary built into the framing of EU-level legal regulation of human gene-editing technologies and identifies its three key related facets: the tension around naturalness; safeguarding morality and ethics; and the pursuit of medical objectives for the protection of human health. Concerns around the use of gene-editing technologies in relation to eugenics and human enhancement have produced a multifaceted imaginary. We argue that this imaginary not only places a limit on EU-level regulation, despite a strong EU competence in respect of the internal market, but also seeks to ensure its legitimation
Prospective purification of perivascular presumptive mesenchymal stem cells from human adipose tissue:process optimization and cell population metrics across a large cohort of diverse demographics
BACKGROUND: Adipose tissue is an attractive source of mesenchymal stem cells (MSC) as it is largely dispensable and readily accessible through minimally invasive procedures such as liposuction. Until recently MSC could only be isolated in a process involving ex-vivo culture and their in-vivo identity, location and frequency remained elusive. We have documented that pericytes (CD45-, CD146+, and CD34-) and adventitial cells (CD45-, CD146-, CD34+) (collectively termed perivascular stem cells or PSC) represent native ancestors of the MSC, and can be prospectively purified using fluorescence activated cell sorting (FACS). In this study we describe an optimized protocol that aims to deliver pure, viable and consistent yields of PSC from adipose tissue. We analysed the frequency of PSC within adipose tissue, and the effect of patient and procedure based variables on this yield. METHODS: Within this twin centre study we analysed the adipose tissue of n = 131 donors using flow cytometry to determine the frequency of PSC and correlate this with demographic and processing data such as age, sex, BMI and cold storage time of the tissue. RESULTS: The mean number of stromal vascular fraction (SVF) cells from 100 ml of lipoaspirate was 34.4 million. Within the SVF, mean cell viability was 83 %, with 31.6 % of cells being haematopoietic (CD45+). Adventitial cells and pericytes represented 33.0 % and 8 % of SVF cells respectively. Therefore, a 200 ml lipoaspirate would theoretically yield 23.2 million viable prospectively purified PSC - sufficient for many reconstructive and regenerative applications. Minimal changes were observed in respect to age, sex and BMI suggesting universal potential application. CONCLUSIONS: Adipose tissue contains two anatomically and phenotypically discreet populations of MSC precursors – adventitial cells and pericytes – together referred to as perivascular stem cells (PSC). More than 9 million PSC per 100 ml of lipoaspirate can be rapidly purified to homogeneity using flow cytometry in clinically relevant numbers potentially circumventing the need for purification and expansion by culture prior to clinical use. The number and viability of PSC are minimally affected by patient age, sex, BMI or the storage time of the tissue, but the quality and consistency of yield can be significantly influenced by procedure based variables. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13287-016-0302-7) contains supplementary material, which is available to authorized users
Does the French Bioethics Law create a "moral exception" to the use of human cells for health? A legal and organizational issue
This article focuses on the legal and
organisational regulation of human cells in the
United Kingdom and France. French Bioethics
Law regulates human cells for health according
to European Union law where it is enforceable.
But products unregulated by EU law
and based on human cells are never considered
as medicinal products, given the strict implementation
of the principle of �nonpatrimonialité�
of the human body and its elements.
By comparison, in the UK such products
can be qualified as medicinal products.
Moreover, the setting up of the UK stem cell
bank gives rise to the development of policies
which expand the stem cell as a legal object.
The paper discusses how these societies� ethical
and legal commitments underlie organisational
practices in order to analyse the
relationship between the existence (or not) of
a national stem cell bank and the broader regulation
of human cells.Este artículo se centra en la regulación
legal y organizativa sobre células humanas en el
Reino Unido y Francia. La ley de bioética
francesa regula las células humanas para la
salud de acuerdo con la legislación de la Unión
Europea, donde ésta tiene vigencia. Sin embargo,
los productos no regulados por la legislación
de la UE que hacen referencia a las
células humanas no son considerados como
medicamentos sujetos a la estricta aplicación
del principio de "no patrimonialidad" del cuerpo
humano y sus elementos. En comparación,
estos productos en el Reino Unido pueden ser
calificados como productos medicinales. Por
otra parte, la creación del banco de células
madre en el Reino Unido da lugar al desarrollo
de políticas de elaboración que se expande a
las célulasmadre en el campo de los objetos jurídicos.
Este artículo muestra cómo los compromisos
éticos y legales que estas sociedades han
adoptado subyacen a las prácticas organizativas
de estos países. Su propósito es analizar la
relación entre la existencia (o no) de un banco
nacional de células madre y la regulación más
amplia del uso de células humanas
Are there specific translational challenges in regenerative medicine? Lessons from other fields
There is concern that translation ‘from bench to bedside’ within regenerative medicine (RM) will fail to materialize, or will be dismally slow, due to various challenges arising from the highly novel and disruptive nature of RM. In this article, we provide a summary of these challenges, and we critically engage with the notion that such challenges are specific to RM. It is important, we argue, not to overstate the exceptional nature of RM, as valuable lessons can be learned from elsewhere in medicine. Using several examples of technology adoption, we suggest that emerging RM products and procedures will have to work hard to find or create an adoption space if translation into the clinic is to be successful